Beginnings of Personalized Medicine for Myeloma

Ajai Chari, MD
Video Categories: Personalized Medicine

Dr. Ajai Chari talks about risk-based treatment for myeloma as the beginning of personalized medicine in the field. The 2 most recent advances are the increased use of proteasome inhibitors for those with the 4;14 translocation and treating those identified with high molecular risk more aggressively.
November 19, 2014

Optimal Value-Based Therapy

Listen as Ken Schaecher, MD discusses the optimal value-based therapy for treatment of polycythemia vera.Supported through funding from Incyte

April 14, 2015

Managing Costs in Oncology Care

Dr. Boccia talks about the importance of controlling costs in the current environment and how the bioT3 testing approach can help compared to other options.